This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange fell 1.94 points to 782.45 Wednesday. Disani Capital Corp. (DSN), an NEX shell controlled by a Vancouver shell-packaging firm, Jeff Durno and Scott Ackerman's Emprise Capital Corp., has submitted a filing statement about its plan to acquire NeutriSci International Inc. The shell received approval from the exchange last month to close the deal.

Disani will roll back its shares 1:3, leaving it with 4,116,149 postconsolidated shares, and then issue 27,035,735 postconsolidated shares to the shareholders of NeutriSci, after which the shell will change its name to that of its target. NeutriSci sells health supplement products in the United States. In March, 2013, it acquired a product line called BluScience from OTCQX-listed ChromaDex Corp. (CDXC: $1.17) for $5.76-million (U.S.), payable in cash, notes and preferred shares. The company pitches the BluScience product line as a do-it-all list of vitamins that are good for the heart, the brain, increasing energy, losing weight and looking younger. To make its product slightly different than all the other products that do the same thing, BluScience adds a special ingredient to each of its products called pterostilbene, which is found in blueberries and grapes. The company claims pterostilbene "is thought to exhibit anti-cancer, anti-hypercholesterolemia, anti-hypertriglyceridemia properties, as well as the ability to fight off and reverse cognitive decline." Consumers have yet to buy into the idea, at least in any numbers. NeutriSci lost $1.46-million on revenue of $223,778 in the nine-month period ended June 30, 2014. The company also used to sell an all-natural sex pill called Vendrome, but revenue was limp and in 2012 the company suspended sales of the product. It will relaunch Vendrome under a new brand next year.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS